The B3GALT6 gene encodes Beta-1,3-Galactosyltransferase 6, a member of the glycosyltransferase family that plays a critical role in the biosynthesis of glycosaminoglycans (GAGs) and proteoglycans. Located on chromosome 2q32.2, this enzyme is essential for the synthesis of the tetrasaccharide linker region that connects glycosaminoglycan chains to the core protein in proteoglycans[mizumoto2012].
| B3GALT6 |
|---|
| Gene Symbol | B3GALT6 |
| Full Name | Beta-1,3-Galactosyltransferase 6 |
| Chromosomal Location | 2q32.2 |
| NCBI Gene ID | [55503](https://www.ncbi.nlm.nih.gov/gene/55503) |
| Ensembl ID | ENSG00000110717 |
| UniProt ID | [Q96MC4](https://www.uniprot.org/uniprotkb/Q96MC4/entry) |
| Protein Category | Glycosyltransferase (GT31 family) |
| OMIM | [614940](https://www.omim.org/entry/614940) |
¶ Gene Structure and Evolution
The B3GALT6 gene spans approximately 8.5 kb and consists of 9 exons. It encodes a type II membrane-bound glycosyltransferase with a short cytoplasmic N-terminus, a transmembrane domain, and a catalytic domain facing the Golgi lumen. The gene is evolutionarily conserved across vertebrates, with orthologs in zebrafish, mice, and humans[byers2012].
¶ Protein Function and Mechanism
B3GALT6 catalyzes the transfer of galactose from UDP-galactose to the growing glycosaminoglycan chain during proteoglycan biosynthesis. Specifically, it functions in the synthesis of the tetrasaccharide linker region (GlcA-β1,3-Gal-β1,3-Gal-β1,4-Xyl) that attaches glycosaminoglycans to the core protein[okajima2007]:
- Substrate: UDP-galactose + acceptor (typically a GlcA-containing trisaccharide)
- Product: Galactosylated tetrasaccharide linker
- Location: Golgi apparatus
- Cooperation: Works together with B4GALT7 (beta-1,4-galactosyltransferase 7) in the linker region synthesis
B3GALT6 shows specificity for:
- Chondroitin sulfate (CS) proteoglycans
- Dermatan sulfate (DS) proteoglycans
- Heparan sulfate (HS) proteoglycans (to lesser extent)
B3GALT6 is widely expressed in connective tissues throughout the body:
- Skin: Dermal fibroblasts, especially in collagen-rich areas
- Cartilage: Chondrocytes in articular and growth plate cartilage
- Bone: Osteoblasts and osteocytes
- Brain: Meningeal cells, some glial populations (lower expression)
- Lung: Bronchial epithelium
- Blood vessels: Vascular smooth muscle cells
The broad expression pattern reflects the ubiquitous role of proteoglycans in extracellular matrix (ECM) organization across all tissues[malfit2015].
Proteoglycans are critical components of the extracellular matrix that provide structural support, regulate growth factor signaling, and maintain tissue hydration[martens2009]:
- Aggrecan: Major proteoglycan in cartilage, provides compressive resistance
- Decorin: Regulates collagen fibril assembly and tissue tensile strength
- Biglycan: Binds to collagen and influences tissue elasticity
- Growth factor binding: Heparan sulfate proteoglycans (HSPGs) bind FGF, VEGF, and other growth factors
- Morphogen gradients: Proteoglycans regulate morphogen diffusion during development
- Cell adhesion: Syndecans and glypicans mediate cell-ECM interactions
Recessive mutations in B3GALT6 cause a novel spectrum of connective tissue disorders characterized by[byers2012]:
- Ehlers-Danlos syndrome (progeroid type): Distinctive facial features, hypermobility, skin fragility
- Arthrochalasia-type EDS: Severe joint hypermobility with congenital dislocation
- Spondyloepimetaphyseal dysplasia: Short stature, skeletal abnormalities
- Loss of enzymatic function reduces proteoglycan synthesis
- Abnormal glycosaminoglycan chains compromise ECM integrity
- Tissues with high mechanical stress are most affected[herguner2015]
While primarily a connective tissue disorder, B3GALT6-related conditions may present with:
- Developmental delay: Due to altered CNS proteoglycans
- Hypotonia: Decreased muscle tone in infancy
- Connective tissue-related neurological complications: Including some cases of spastic paraplegia[cathey2010]
Although not directly linked to classic neurodegenerative diseases, glycosyltransferases like B3GALT6 are increasingly recognized in neurodegenerative processes[esko2009]:
- Alzheimer's disease: Heparan sulfate proteoglycans interact with amyloid-beta and tau, influencing plaque formation and neurofibrillary tangle development[yamaguchi2000]
- Parkinson's disease: Altered proteoglycan metabolism affects alpha-synuclein aggregation
- Axon guidance: Proteoglycans regulate growth cone navigation during development[yamada2014]
¶ Glycosylation and Neuroinflammation
- Alterations in glycosylation patterns affect microglial activation
- Changes in ECM glycosaminoglycans modulate neuroinflammatory responses[uyama2013]
Understanding glycosyltransferase function may lead to:
- Targeted therapies: Modulating proteoglycan synthesis to influence disease progression
- Biomarkers: Glycosylation patterns as indicators of disease state
- Gene therapy: Restoring enzymatic function in deficiency states
- Zebrafish models: B3GALT6 knockdown shows craniofacial and fin development defects
- Mouse models: Conditional knockouts demonstrate skin and cartilage abnormalities
- Patient-derived cells: Fibroblasts show reduced GAG synthesis capacity
- Symptomatic management: Physical therapy, orthopedic interventions for joint issues
- Monitoring: Regular assessment of cardiac, ophthalmological, and skeletal complications
- Genetic counseling: Family planning and carrier identification
- Enzyme replacement: Potential for supplying functional glycosyltransferase
- Gene therapy: AAV-mediated B3GALT6 delivery
- Small molecule modulators: Enhancing residual enzyme activity
- Mizumoto et al., Functional analysis of B3GALT6 (2012)
- Kurtoglu et al., B3GALT6 syndrome (2014)
- Byers et al., Mutations in B3GALT6 cause connective tissue disorders (2012)
- Malfait et al., International classification of connective tissue disorders (2015)
- Herguner et al., B3GALT6 in Ehlers-Danlos syndrome (2015)
- Guo et al., B3GALT6 regulates extracellular matrix (2015)
- Okajima et al., Molecular functions of glycosyltransferases (2007)
- Esko et al., Proteoglycans in neurodegeneration (2009)
- Karamanos et al., Glycosaminoglycans in health and disease (2019)
- Yamada et al., Glycosyltransferases in brain development (2014)
- Uyama et al., Disorders of glycosylation in neurological diseases (2013)
- Martens et al., Proteoglycans in the central nervous system (2009)
- Cunningham et al., Glycosyltransferase mutations in skeletal dysplasia (2016)
- Faiyaz et al., Founder mutation in B3GALT6 (2014)
- Morvan et al., Glycosylation in neurodegenerative diseases (2019)
- Cathey et al., Phenotypic spectrum of B3GALT6-related disorders (2010)
- Peyrin et al., Proteoglycans in tau aggregation (2007)
- Berenson et al., Heparan sulfate in tau pathology (2010)
- Yamaguchi et al., Glycosaminoglycans in Alzheimer's disease (2000)
- Jourdain et al., Proteoglycans at the synapse (2018)